An Open-label Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia

  • STATUS
    Recruiting
  • days left to enroll
    57
  • participants needed
    80
  • sponsor
    Kurume University
Send
Updated on 16 October 2021
See if I qualify
ramelteon
suvorexant
lemborexant

Summary

This study will be conducted to evaluate whether the approach of direct transitioning to lemborexant (LEM) is supported for insomnia patients who are unsatisfied with current medication.

Transition from Following 4 regimens of interest will be investigated; Z-Drug monotherapy, suvorexant (SUV) monotherapy, SUV and benzodiazepine receptor agonists (BZRA) combination therapy, and ramelteon (RMT) and BZRA combination therapy. Patients with insomnia who have been treated with one of the regimens but do not have treatment satisfaction will be enrolled.

As a comprehensive indicator of patient satisfaction including treatment efficacy and safety, the proportion of patients with successful transitioning will be evaluated at 2 weeks after transitioning; thus important initial response after transitioning will be evaluated as a primary endpoint. In addition, as a secondary purpose, the treatment continuation, efficacy and tolerability, and the treatment impression for insomnia (Patient Global Impression of Insomnia) for 14 weeks after transitioning will be assessed.

Details
Condition Insomnia
Treatment Lemborexant (LEM) 5 mg (Z-Drug-mono cohort), Lemborexant (LEM) 5 mg (SUV-mono cohort), Lemborexant (LEM) 5 mg (SUV-combination cohort), Lemborexant (LEM) 5 mg (RMT-combination cohort)
Clinical Study IdentifierNCT04742699
SponsorKurume University
Last Modified on16 October 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Subjects who have voluntarily provided a written informed consent to participate in the study
Subjects with insomnia aged 20 years or older at the time of informed consent
Subjects who are dissatisfied with the efficacy or tolerability of prior medications and wish to transition from them. For example
Subjects who are treated with Z-Drug monotherapy or a combination of BZRA and RMT, and have particularly difficulties with sleep maintenance
Subjects who are treated with SUV monotherapy or a combination of BZRA and SUV, and have particularly difficulties with sleep onset
Subjects who are treated with a combination therapy of BZRA and SUV or BZRA and RMT, and wish to reduce or discontinue BZRA
Subjects with frequent use (i.e. at least 5 nights a week) of Z-drug monotherapy, SUV monotherapy, combination therapy with BZRA and SUV, or combination therapy with BZRA and RMT in the month before the start of the pretreatment phase
Subjects who meet the criteria for insomnia disorder in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) as follows
Despite an adequate opportunity for sleep, subjects have night sleep-related complaints accompanied by at least 1 of the following symptoms: difficulty in falling asleep, difficulty in staying asleep, and waking up early
The difficulty in sleeping occurs at least 3 nights a week
The difficulty in sleeping persists for at least 3 months
The difficulty in sleeping causes daytime dysfunction
Subjects who can secure at least 7 hours for sleep
Subjects who have a documented use of a prior medication(s) for the treatment of insomnia at least 5 nights in the last 2 weeks of the pretreatment phase
Subjects who are able to comply with the requirements specified in the study protocol

Exclusion Criteria

Female who are breastfeeding or pregnant at pretreatment phase. If pregnancy cannot be completely denied by interview, a serum beta-hCG test will be performed
Females of childbearing potential who did not use a highly effective method of contraception, which includes
total abstinence (if it is their preferred and usual lifestyle)
use of condom
an intrauterine device (IUD)
a contraceptive implant
an oral or an injective contraceptive
have a vasectomized partner with confirmed azoospermia; The following methods are not considered as contraception: periodic abstinence such as calendar method, ovulation method, symptothermal method, basal body temperature method, and withdrawal method
Do not agree to use a highly effective method of contraception (as described above)
Subjects with moderate or severe obstructive sleep apnea (OSA)
Subjects with any symptoms and/or disease that may affect the safety or the endpoints of the study in the opinion of the investigator (see the examples below)
Cardiac disorder [including subjects with repeated QT interval prolongation1 in previous ECG tests. For subjects whose QT interval abnormality cannot be ruled out by interview, ECG tests should be performed by baseline (Visit 2) to confirm the normality of corrected QT (QTc) interval]
QT interval corrected by Fridericia's formulas (QTcF) exceeds 450 ms
Respiratory disorder other than mild OSA
Digestive disease
Kidney disease [including renal dysfunction]
Neurological disorders [including intellectual incapacity or cognitive decline with disorientation to the person, place, time or situation]
Mental disorders
Chronic pain [pain disorders]
Carcinoma within 5 years [excluding appropriately treated basal cell carcinoma] 5. Subjects who currently have certain sleep disorders other than insomnia such as periodic limb movement disorder, restless legs syndrome, and circadian rhythm sleep disorder. Subjects diagnosed with mild OSA are not excluded from the study 6. Subjects who currently have a habit of napping for a long period of time 3 or more times a week in the opinion of the investigator. 7. Subjects who currently have narcolepsy or cataplexy 8. Subjects who are using a prior medication(s) for the treatment of insomnia at doses exceeding the dosage and administration approved in Japan 9. Subjects who are using two or more BZRAs 10. Subjects who are using sedative medication(s) 11. Have used prohibited concomitant drugs within 1 week before the start of the pretreatment phase 12. Have newly started nonpharmacologic treatments for insomnia (eg, cognitive behavioral therapy) within 1 week before the pretreatment phase 13. Subjects who cannot refrain from excessive alcohol consumption during study participation 14. Subjects with a history of hypersensitivity to any of the excipients of LEM 15. Subjects with moderate or severe hepatic impairment (subjects whose AST, ALT, or gamma-GTP is 3 times or more the upper limit of the institutional reference interval) 16. History of antipsychotic drugs use within the past 2 years or attempted suicide, which may affect the safety or the endpoints of the study in the opinion of the investigator 17. Subjects who have previously taken LEM (including subjects who have participated in a clinical trial of LEM) 18. Subjects deemed inappropriate to participate in this study in the opinion of the investigator
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ramelteon
suvorexant
lemborexant

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note